Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 909-911

  Salvadori, M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ASPERGILLOSIS; BLOOD TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEART INFARCTION; HUMAN; ILEUS; INFECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN CARCINOMA; TREATMENT OUTCOME;

EID: 17844371360     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.01.063     Document Type: Conference Paper

References (3)

1. A.O. Ojo, H.-U. Meier-Kriesche, J.A. Hanson Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection Transplantation 69 2000 2405
2. K. Budde, P. Glander, U. Hahn Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance transplant patients Am J Transplant 2 2002 399 (Abstract)
3. M. Salvadori, H. Holzer, A. de Mattos Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients Am J Transplant 4 2003 231